Study reveals 70% of Post-Pfizer COVID-19 deaths in Japan occurred within 10 days of vaccination

A peer-reviewed Japanese study, published in the journal Cureus, has revealed that nearly 70 percent of individuals who died after receiving the Pfizer COVID-19 vaccine in Japan passed away within the first 10 days of vaccination.

The study, which analyzed death patterns following vaccination, raises questions about the potential risk period immediately after inoculation.

Researchers examined data from the Japanese Ministry of Health, Labor, and Welfare (MHLW) involving deaths linked to the Pfizer-BioNTech (BNT162b2) mRNA vaccine from February 2021 to March 2023.

The study divided the subjects into two age groups: Group 1, individuals aged 65 and above, and Group 2, individuals aged 64 and younger.

The findings revealed that 71 percent of deaths in Group 1 and 70 percent in Group 2 occurred within the 10-day period post-vaccination, with many deaths reported on the first, third, and fourth days.

Group 1, comprising 1,311 individuals, saw more female deaths in the first 10 days due to various medical conditions, while the trend reversed after this period, with more male fatalities.

In Group 2, which included 247 individuals, male deaths significantly outnumbered female deaths in the early risk period.

The leading causes of death in the older age group (Group 1) included ischemic heart disease, heart failure, and aspiration pneumonia. Meanwhile, younger adults (Group 2) experienced fatalities primarily from ischemic heart disease, cardiac arrhythmias, and subarachnoid hemorrhage.

READ ALSO: Experts condemn LASG’s HPV vaccine push in schools, cites health, ethical concer

Researchers also noted an elevated risk of myocarditis and pericarditis, particularly among men in the first 10 days post-vaccination.

The study highlighted several limitations, including the small number of autopsies conducted and the difficulty in distinguishing between incidental and vaccine-related deaths.

Despite these challenges, the findings suggest that the Pfizer COVID-19 vaccine may play a role in influencing death rates within the 10-day risk period.

Study author Yasusi Suzumura emphasized that while vaccines are designed for healthy individuals, they should maintain a high safety profile.

He called for further analysis using statistical methods to determine the true impact of vaccines on mortality, warning that even with a low vaccination mortality rate, continued monitoring and safety assessments are critical.

The researchers also acknowledged that not all deaths reported to MHLW were directly related to the vaccine, and some may have been coincidental.

Nevertheless, they stressed that the study’s insights could prove valuable in improving vaccine safety protocols moving forward.